Nimodip

Nimodip is a small-molecule pharmaceutical agent studied as a calcium channel blocker with a focus on cerebral vessels. It is described as acting on L-type voltage-gated calcium channels to reduce calcium entry into vascular smooth muscle, promoting vasodilation with a preference for cerebral arteries in some preclinical models.

Clinical development of Nimodip has centered on preventing or treating cerebral vasospasm after aneurysmal subarachnoid hemorrhage and improving cerebral perfusion. Evidence from early studies suggests potential benefits in selected patients, but Nimodip is not broadly approved for any indication in major regulatory jurisdictions. Access is typically limited to clinical trials or restricted programs where available.

Pharmacokinetics of Nimodip include oral administration with variable bioavailability and extensive hepatic metabolism. Metabolites are typically excreted in urine and feces. The elimination half-life is on the order of several hours, and systemic exposure depends on dosing and liver function.

Adverse effects associated with Nimodip may resemble those of other dihydropyridine calcium channel blockers, including headache, dizziness, flushing, nausea, and hypotension. More serious risks can include syncope and liver function abnormalities, particularly when used with other antihypertensives or with strong inhibitors or inducers of cytochrome P450 3A4. Caution is advised in patients with hepatic impairment or concurrent use of other calcium channel blockers.

Regulatory status and research: Nimodip is not approved for general medical use in most countries. Ongoing research seeks to clarify its safety, dosing, and efficacy in cerebrovascular conditions. See also nimodipine for related context.